These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31628201)

  • 21. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
    Kilbride KE; Lee MC; Nees AV; Cimmino VM; Diehl KM; Sabel MS; Hayes DF; Schott AF; Kleer CG; Chang AE; Newman LA
    Ann Surg Oncol; 2008 Nov; 15(11):3252-8. PubMed ID: 18784961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.
    Jones JL; Zabicki K; Christian RL; Gadd MA; Hughes KS; Lesnikoski BA; Rhei E; Specht MC; Dominguez FJ; Smith BL
    Am J Surg; 2005 Oct; 190(4):517-20. PubMed ID: 16164912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 26. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
    Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
    Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of gamma probe-assisted intraoperative sentinel lymph node evaluation in predicting axillary breast cancer metastasis after neoadjuvant chemotherapy.
    Berberoglu K; Erdemir A; Rasa K; Baloglu H; Cakmakci M
    Nucl Med Commun; 2020 Feb; 41(2):120-125. PubMed ID: 31764597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
    Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
    Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
    Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
    Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis.
    Yokotani T; Ikeda N; Hirao T; Tanaka Y; Morita K; Fujii T; Ohbayashi C; Nakamura T; Kobayashi T; Sho M
    Surg Today; 2021 Apr; 51(4):595-604. PubMed ID: 33052489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
    Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements.
    Nagashima T; Sakakibara M; Kadowaki M; Suzuki TH; Yokomizo J; Ohki Y; Miyoshi T; Kazama T; Nakatani Y; Miyazaki M
    Acta Radiol; 2011 Apr; 52(3):241-6. PubMed ID: 21498357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
    Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
    J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
    Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
    Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer.
    Oruwari JU; Chung MA; Koelliker S; Steinhoff MM; Cady B
    Am J Surg; 2002 Oct; 184(4):307-9. PubMed ID: 12383889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment.
    Qu LT; Peters S; Cobb AN; Godellas CV; Perez CB; Vaince FT
    Am J Surg; 2018 Mar; 215(3):530-533. PubMed ID: 29246403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
    Breslin TM; Cohen L; Sahin A; Fleming JB; Kuerer HM; Newman LA; Delpassand ES; House R; Ames FC; Feig BW; Ross MI; Singletary SE; Buzdar AU; Hortobagyi GN; Hunt KK
    J Clin Oncol; 2000 Oct; 18(20):3480-6. PubMed ID: 11032588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.